Leucovorin (Folinic Acid) Dosing Recommendations
Methotrexate Rescue After High-Dose Methotrexate
For high-dose methotrexate (12-15 g/m²), leucovorin rescue should be initiated at 15 mg (approximately 10 mg/m²) every 6 hours for 10 doses starting 24 hours after the beginning of methotrexate infusion 1. This represents the FDA-approved standard dosing regimen.
Dosing Algorithm Based on Methotrexate Levels:
Normal Elimination:
- MTX level ~10 micromolar at 24h, ~1 micromolar at 48h, <0.2 micromolar at 72h
- Continue standard 15 mg every 6 hours for 60 hours (10 doses) 1
Delayed Late Elimination:
- MTX level >0.2 micromolar at 72h and >0.05 micromolar at 96h
- Continue 15 mg every 6 hours until MTX level <0.05 micromolar 1
Delayed Early Elimination/Acute Renal Injury:
- MTX level ≥50 micromolar at 24h OR ≥5 micromolar at 48h OR 100% increase in serum creatinine at 24h
- Escalate to 150 mg IV every 3 hours until MTX <1 micromolar, then 15 mg every 3 hours until MTX <0.05 micromolar 1
- These patients require aggressive hydration, urinary alkalinization (pH ≥7.0), and close fluid/electrolyte monitoring 1
Critical Timing Considerations:
The effectiveness of leucovorin decreases as the time interval between methotrexate administration and rescue increases 2. When methotrexate overdose is suspected or worrisome decrements in blood counts occur, leucovorin at 10 mg/m² should be administered immediately with subsequent doses every 6 hours 2. For intermediate-dose methotrexate (5-6 g/m²), rescue should be started no later than 36 hours from the start of infusion to avoid considerable toxicity 3.
Low-Dose Methotrexate Toxicity (Psoriasis/Rheumatoid Arthritis)
For hematologic toxicity from low-dose weekly methotrexate, folinic acid at 10 mg/m² should be administered immediately when overdose is suspected or significant blood count decrements occur, with subsequent doses every 6 hours 2.
A randomized controlled trial comparing 15 mg versus 25 mg leucovorin every 6 hours for severe low-dose methotrexate toxicity found no significant difference in mortality (42% vs 47%) or hematological recovery between doses 4. This suggests that 15 mg every 6 hours is adequate for severe low-dose methotrexate toxicity.
5-Fluorouracil Modulation (Colorectal Cancer)
Leucovorin is used to enhance 5-FU efficacy, not as rescue. Two FDA-approved regimens exist 1:
Regimen 1:
- Leucovorin 200 mg/m² IV over minimum 3 minutes, followed by 5-FU 370 mg/m² IV
- Daily for 5 days, repeated every 28 days for 2 courses, then every 28-35 days 1
Regimen 2:
- Leucovorin 20 mg/m² IV, followed by 5-FU 425 mg/m² IV
- Daily for 5 days, repeated every 28 days for 2 courses, then every 28-35 days 1
Leucovorin doses are not adjusted for toxicity; only 5-FU doses are modified based on tolerance 1.
Pyrimethamine-Induced Bone Marrow Suppression
Concurrent administration of folinic acid is strongly recommended when pyrimethamine is used for toxoplasmosis treatment 5. If signs of folate deficiency or bone marrow suppression develop, pyrimethamine should be discontinued and folinic acid (leucovorin) administered until normal hematopoiesis is restored 5. The specific dose is not defined in the FDA label, but the principle is to continue until blood counts normalize.
Folate Deficiency
Leucovorin is not the standard treatment for simple folate deficiency—folic acid is preferred as it is less expensive and equally effective 6. Leucovorin is reserved for situations where rapid folate repletion is needed or when dihydrofolate reductase is inhibited (methotrexate, pyrimethamine).
Important Caveats:
- Never administer leucovorin intrathecally 1
- Monitor serum creatinine and methotrexate levels at least daily during high-dose methotrexate rescue 1
- Consider drug interactions that may impair methotrexate elimination (NSAIDs, penicillins, sulfonamides) when determining leucovorin needs 1
- In gastrointestinal toxicity with nausea/vomiting, administer leucovorin parenterally rather than orally 1